NCT06799416View on ClinicalTrials.gov

A Study to Assess the Safety of ARGX-109 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

August 8, 2025

Study Completion Date

August 8, 2025

Conditions

Healthy Volunteer

Interventions

BIOLOGICAL

ARGX-109

administrations of ARGX-109

OTHER

Placebo

administrations of placebo comparator

Trial Locations (1)

H3P 3P1

Altasciences - Montreal - Phase I unit, Mount Royal

Sponsors

Lead Sponsor

All Listed Sponsors

lead

argenx

INDUSTRY

NCT06799416 - A Study to Assess the Safety of ARGX-109 in Healthy Volunteers | Biotech Hunter | Biotech Hunter